Please disable your adblock and script blockers to view this page

FDA approves Johnson & Johnson's ketamine-like nasal spray for depression


InThe U.S. Food and Drug Administration
Johnson & Johnson's
FDA
Spravato
K.The
Center for Drug Evaluation and Research
J&J
CNBC
CNBC LLC
All Rights Reserved
Division
NBCUniversalData
Global Business and Financial News
Market Data and Analysis


Tiffany Farchione
Janssen

No matching tags

No matching tags

No matching tags

No matching tags

No matching tags

Positivity     30.00%   
   Negativity   70.00%
The New York Times
SOURCE: https://www.cnbc.com/2019/03/06/us-fda-approves-jjs-ketamine-like-nasal-spray-for-depression.html
Write a review: CNBC
Summary

The U.S. Food and Drug Administration on Tuesday said it approved Johnson & Johnson's nasal spray antidepressant that is chemically similar to often-abused ketamine, marking the first advance in treating depression in more than 30 years.

As said here by Reuters